Blocking the interaction between apolipoprotein E and Aβ reduces intraneuronal accumulation of Aβ and inhibits synaptic degeneration.

[1]  D. Holtzman,et al.  Apolipoprotein E, Especially Apolipoprotein E4, Increases the Oligomerization of Amyloid β Peptide , 2012, The Journal of Neuroscience.

[2]  Steven Hou,et al.  Apolipoprotein E4 effects in Alzheimer's disease are mediated by synaptotoxic oligomeric amyloid-β. , 2012, Brain : a journal of neurology.

[3]  Donald A. Wilson,et al.  ApoE-Directed Therapeutics Rapidly Clear β-Amyloid and Reverse Deficits in AD Mouse Models , 2012, Science.

[4]  D. Holtzman,et al.  Low-density Lipoprotein Receptor Represents an Apolipoprotein E-independent Pathway of Aβ Uptake and Degradation by Astrocytes* , 2012, The Journal of Biological Chemistry.

[5]  D. Holtzman,et al.  Haploinsufficiency of Human APOE Reduces Amyloid Deposition in a Mouse Model of Amyloid-β Amyloidosis , 2011, The Journal of Neuroscience.

[6]  David M Holtzman,et al.  Human apoE Isoforms Differentially Regulate Brain Amyloid-β Peptide Clearance , 2011, Science Translational Medicine.

[7]  E. Masliah,et al.  ApoE4-Driven Accumulation of Intraneuronal Oligomerized Aβ42 following Activation of the Amyloid Cascade In Vivo Is Mediated by a Gain of Function , 2011, International journal of Alzheimer's disease.

[8]  C. Rowe,et al.  Longitudinal assessment of Aβ and cognition in aging and Alzheimer disease , 2011, Annals of neurology.

[9]  Su Jeong Park,et al.  Rapid and Direct Detection of Apolipoprotein E Genotypes Using Whole Blood from Humans , 2010, Journal of toxicology and environmental health. Part A.

[10]  G. Bu,et al.  Low-Density Lipoprotein Receptor-Related Protein 1 (LRP1) Mediates Neuronal Aβ42 Uptake and Lysosomal Trafficking , 2010, PloS one.

[11]  Michael T. Lin,et al.  Co-occurrence of Alzheimer's disease β-amyloid and tau pathologies at synapses , 2010, Neurobiology of Aging.

[12]  E. Capetillo-Zarate,et al.  Intraneuronal β-amyloid accumulation and synapse pathology in Alzheimer’s disease , 2010, Acta Neuropathologica.

[13]  D. Holtzman,et al.  Overexpression of Low-Density Lipoprotein Receptor in the Brain Markedly Inhibits Amyloid Deposition and Increases Extracellular Aβ Clearance , 2009, Neuron.

[14]  G. McKhann,et al.  RAGE-mediated signaling contributes to intraneuronal transport of amyloid-β and neuronal dysfunction , 2009, Proceedings of the National Academy of Sciences.

[15]  D. Holtzman,et al.  The Role of Apolipoprotein E in Alzheimer's Disease , 2009, Neuron.

[16]  F. Liu,et al.  Human APOE Isoform-Dependent Effects on Brain β-Amyloid Levels in PDAPP Transgenic Mice , 2009, The Journal of Neuroscience.

[17]  T. Wisniewski,et al.  Anti-PrP Mab 6D11 suppresses PrPSc replication in prion infected myeloid precursor line FDC-P1/22L and in the lymphoreticular system in vivo , 2009, Neurobiology of Disease.

[18]  M. Davidson,et al.  Mechanism of Neuronal versus Endothelial Cell Uptake of Alzheimer's Disease Amyloid β Protein , 2009, PloS one.

[19]  D. Holtzman,et al.  ApoE Promotes the Proteolytic Degradation of Aβ , 2008, Neuron.

[20]  E. Masliah,et al.  Activation of the Amyloid Cascade in Apolipoprotein E4 Transgenic Mice Induces Lysosomal Activation and Neurodegeneration Resulting in Marked Cognitive Deficits , 2008, The Journal of Neuroscience.

[21]  S. Kar,et al.  Internalization of β-Amyloid Peptide by Primary Neurons in the Absence of Apolipoprotein E* , 2007, Journal of Biological Chemistry.

[22]  Roger M. Nitsch,et al.  Intracellular Aβ and cognitive deficits precede β-amyloid deposition in transgenic arcAβ mice , 2007, Neurobiology of Aging.

[23]  Kim N. Green,et al.  Intracellular amyloid-β in Alzheimer's disease , 2007, Nature Reviews Neuroscience.

[24]  C. Almeida,et al.  Internalized Antibodies to the Aβ Domain of APP Reduce Neuronal Aβ and Protect against Synaptic Alterations*♦ , 2007, Journal of Biological Chemistry.

[25]  Bernardo L Sabatini,et al.  Natural Oligomers of the Alzheimer Amyloid-β Protein Induce Reversible Synapse Loss by Modulating an NMDA-Type Glutamate Receptor-Dependent Signaling Pathway , 2007, The Journal of Neuroscience.

[26]  W. Klein,et al.  Aβ Oligomer-Induced Aberrations in Synapse Composition, Shape, and Density Provide a Molecular Basis for Loss of Connectivity in Alzheimer's Disease , 2007, The Journal of Neuroscience.

[27]  D. Quartermain,et al.  Blocking the apolipoprotein E/amyloid-β interaction as a potential therapeutic approach for Alzheimer's disease , 2006, Proceedings of the National Academy of Sciences.

[28]  Brian J. Bacskai,et al.  Characterization of amyloid deposition in the APPswe/PS1dE9 mouse model of Alzheimer disease , 2006, Neurobiology of Disease.

[29]  D. Holtzman,et al.  Apolipoprotein E and Low Density Lipoprotein Receptor-related Protein Facilitate Intraneuronal Aβ42 Accumulation in Amyloid Model Mice* , 2006, Journal of Biological Chemistry.

[30]  M. Ohno,et al.  Intraneuronal β-Amyloid Aggregates, Neurodegeneration, and Neuron Loss in Transgenic Mice with Five Familial Alzheimer's Disease Mutations: Potential Factors in Amyloid Plaque Formation , 2006, The Journal of Neuroscience.

[31]  M. Sadowski,et al.  Clearance and prevention of prion infection in cell culture by anti‐PrP antibodies , 2006, The European journal of neuroscience.

[32]  C. Almeida,et al.  β-Amyloid Accumulation Impairs Multivesicular Body Sorting by Inhibiting the Ubiquitin-Proteasome System , 2006, The Journal of Neuroscience.

[33]  P. Greengard,et al.  Beta-amyloid accumulation in APP mutant neurons reduces PSD-95 and GluR1 in synapses , 2005, Neurobiology of Disease.

[34]  Michael D. Ehlers,et al.  Homeostatic plasticity and NMDA receptor trafficking , 2005, Trends in Neurosciences.

[35]  J. D. McGaugh,et al.  Intraneuronal Aβ Causes the Onset of Early Alzheimer’s Disease-Related Cognitive Deficits in Transgenic Mice , 2005, Neuron.

[36]  C. Finch,et al.  Synaptic Targeting by Alzheimer's-Related Amyloid β Oligomers , 2004, The Journal of Neuroscience.

[37]  R. Deane,et al.  RAGE (Yin) Versus LRP (Yang) Balance Regulates Alzheimer Amyloid &bgr;-Peptide Clearance Through Transport Across the Blood–Brain Barrier , 2004, Stroke.

[38]  Thomas Wisniewski,et al.  A synthetic peptide blocking the apolipoprotein E/β-amyloid binding mitigates β-amyloid toxicity and fibril formation in vitro and reduces β-amyloid plaques in transgenic mice , 2004 .

[39]  R. Tanzi,et al.  Clearance of Alzheimer's Aβ Peptide The Many Roads to Perdition , 2004, Neuron.

[40]  Xi Chen,et al.  Materials and Methods Som Text Figs. S1 and S2 Table S1 References Abad Directly Links A␤ to Mitochondrial Toxicity in Alzheimer's Disease , 2022 .

[41]  C. Almeida,et al.  Oligomerization of Alzheimer's β-Amyloid within Processes and Synapses of Cultured Neurons and Brain , 2004, The Journal of Neuroscience.

[42]  D. Holtzman,et al.  Increased soluble amyloid-beta peptide and memory deficits in amyloid model mice overexpressing the low-density lipoprotein receptor-related protein. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[43]  C. Finch,et al.  Self-assembly of Aβ1-42 into globular neurotoxins , 2003 .

[44]  M. Mattson,et al.  Triple-Transgenic Model of Alzheimer's Disease with Plaques and Tangles Intracellular Aβ and Synaptic Dysfunction , 2003, Neuron.

[45]  Carl W. Cotman,et al.  Common Structure of Soluble Amyloid Oligomers Implies Common Mechanism of Pathogenesis , 2003, Science.

[46]  G. Krafft,et al.  In Vitro Characterization of Conditions for Amyloid-β Peptide Oligomerization and Fibrillogenesis* , 2003, The Journal of Biological Chemistry.

[47]  David J. Cummins,et al.  Peripheral anti-Aβ antibody alters CNS and plasma Aβ clearance and decreases brain Aβ burden in a mouse model of Alzheimer's disease , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[48]  A. Fagan,et al.  Apolipoprotein E facilitates neuritic and cerebrovascular plaque formation in an Alzheimer's disease model , 2000, Annals of neurology.

[49]  N. Maeda,et al.  Type III hyperlipoproteinemia and spontaneous atherosclerosis in mice resulting from gene replacement of mouse Apoe with human Apoe*2. , 1998, The Journal of clinical investigation.

[50]  J. Wegiel,et al.  Diffuse, Lake-like Amyloid-β Deposits in the Parvopyramidal Layer of the Presubiculum in Alzheimer Disease , 1998, Journal of neuropathology and experimental neurology.

[51]  S. Paul,et al.  Lack of apolipoprotein E dramatically reduces amyloid β-peptide deposition , 1997, Nature Genetics.

[52]  N. Maeda,et al.  Targeted Replacement of the Mouse Apolipoprotein E Gene with the Common Human APOE3 Allele Enhances Diet-induced Hypercholesterolemia and Atherosclerosis* , 1997, The Journal of Biological Chemistry.

[53]  P. Roux,et al.  Reactive Astroglia Support Primary Dendritic but Not Axonal Outgrowth from Mouse Cortical Neuronsin Vitro , 1996, Experimental Neurology.

[54]  H. Brewer,et al.  Amyloid-associated proteins α1-antichymotrypsin and apolipoprotein E promote assembly of Alzheimer β-protein into filaments , 1994, Nature.

[55]  N. Maeda,et al.  Spontaneous hypercholesterolemia and arterial lesions in mice lacking apolipoprotein E. , 1992, Science.

[56]  M. Mattson,et al.  Developmental expression, compartmentalization, and possible role in excitotoxicity of a putative NMDA receptor protein in cultured hippocampal neurons , 1991, Brain Research.

[57]  D. Selkoe.  Alzheimer's disease. , 2011, Cold Spring Harbor perspectives in biology.

[58]  W. Klein,et al.  Abeta oligomer-induced aberrations in synapse composition, shape, and density provide a molecular basis for loss of connectivity in Alzheimer's disease. , 2007, The Journal of neuroscience : the official journal of the Society for Neuroscience.

[59]  R. Nitsch,et al.  Intracellular Abeta and cognitive deficits precede beta-amyloid deposition in transgenic arcAbeta mice. , 2007, Neurobiology of aging.

[60]  C. Almeida,et al.  Internalized antibodies to the Abeta domain of APP reduce neuronal Abeta and protect against synaptic alterations. , 2007, The Journal of biological chemistry.

[61]  F. LaFerla,et al.  Intracellular amyloid-beta in Alzheimer's disease. , 2007, Nature reviews. Neuroscience.

[62]  P. Greengard,et al.  Regulation of NMDA receptor trafficking by amyloid-beta. , 2005, Nature neuroscience.

[63]  D. Holtzman,et al.  A synthetic peptide blocking the apolipoprotein E/beta-amyloid binding mitigates beta-amyloid toxicity and fibril formation in vitro and reduces beta-amyloid plaques in transgenic mice. , 2004, The American journal of pathology.

[64]  C. Finch,et al.  Synaptic targeting by Alzheimer's-related amyloid beta oligomers. , 2004, The Journal of neuroscience : the official journal of the Society for Neuroscience.

[65]  R. Tanzi,et al.  Clearance of Alzheimer's Abeta peptide: the many roads to perdition. , 2004, Neuron.

[66]  C. Finch,et al.  Self-assembly of Abeta(1-42) into globular neurotoxins. , 2003, Biochemistry.

[67]  D. Holtzman,et al.  Peripheral anti-A beta antibody alters CNS and plasma A beta clearance and decreases brain A beta burden in a mouse model of Alzheimer's disease. , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[68]  J. Ma,et al.  Amyloid-associated proteins alpha 1-antichymotrypsin and apolipoprotein E promote assembly of Alzheimer beta-protein into filaments. , 1994, Nature.

[69]  J. Rose,et al.  Journal of Neuroinflammation Microglial Inhibition of Neuroprotection by Antagonists of the Ep1 Prostaglandin E2 Receptor , 2022 .